Corium International, Inc., Announces $40 Million Financing lead by Essex Woodlands Health Ventures
MenloPark, CA
Menlo Park, CA, September 26, 2007 — Corium International, Inc., a privately-held transdermal drug delivery company, today announced that it has completed a $25.1 million Series C financing led by Essex Woodlands Health Ventures. Quantum Technology Partners, Aphelion Capital and a strategic investor also participated in the round. In connection with the financing, StrataGent Life Sciences, Inc., an Essex Woodlands Health Ventures portfolio company focused on needlefree delivery of drugs, will merge into Corium. Corium and Essex Woodlands Health Ventures have also set terms for a $15.2 million Series D financing to occur within 24 months, subject to certain conditions. Seven Hills Partners LLC acted as Corium’s exclusive financial advisor and placement agent in these transactions…